In 2022, the FDA approved numerous new drug and biologic agents, including targeted small molecules, immunotherapeutics, a gene therapy and a radiopharmaceutical. Several drug development challenges were also addressed, and key focus areas for the FDA Oncology Center of Excellence included ongoing monitoring of the Accelerated Approval programme and drug dose optimization.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tew, W. P., Lacchetti, C. & Kohn, E. C. Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J. Clin. Oncol. 40, 3878–3881 (2022).
Richardson, N. C., Kasamon, Y., Pazdur, R. & Gormley, N. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol. 23, 563–566 (2022).
Secura Bio, Inc.; Withdrawal of approval of relapsed or refractory follicular lymphoma indication for COPIKTRA. 87 Fed. Reg. 21888 (13 April 2022).
FDA. Oncologic Drugs Advisory Committee (ODAC) meeting. fda.gov, https://www.fda.gov/media/159920/download (21 April 2022).
FDA. Oncologic Drugs Advisory Committee (ODAC) meeting. fda.gov, https://www.fda.gov/media/164051/download (23 September 2022).
FDA. Oncologic Drugs Advisory Committee (ODAC) meeting. fda.gov, https://www.fda.gov/media/164050/download (22 September 2022).
FDA. Oncologic Drugs Advisory Committee (ODAC) meeting. fda.gov, https://www.fda.gov/media/164049/download (22 September 2022).
FDA. Conversations on Cancer. fda.gov, https://www.fda.gov/about-fda/project-community/conversations-cancer (accessed 13 January 2023).
FDA. Oncologic Drugs Advisory Committee (ODAC) meeting. fda.gov, https://www.fda.gov/media/164232/download (28 October 2022).
FDA. Oncology Center of Excellence guidance documents. fda.gov, https://www.fda.gov/media/157635/download (6 April 2022).
Acknowledgements
The authors thank P. Kluetz and M. Theoret (both based at the US FDA) for their assistance with writing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Telaraja, D., Gormley, N. & Pazdur, R. Approvals in 2022: overall survival, dose optimization, new approvals and beyond. Nat Rev Clin Oncol 20, 207–208 (2023). https://doi.org/10.1038/s41571-023-00741-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00741-6
